

Cryoballoon ablation & pulse-field ablation

Prof. Dr. Kyoung-Ryul Julian Chun

Catheter ablation of atrial fibrillation (AF) is evolving towards first line therapy with proven benefits demonstrated in numerous randomized clinical trials. The advent of novel technologies such as the single shot cryoballoon has been a key driver in the field increasing safety and reproducibility of pulmonary vein isolation (PVI) worldwide. However, as with all thermal ablation energy sources cryoballoon PVI may be related to side effects such as esophageal lesions and phrenic nerve palsy. In contrast, the recently re-discovered pulsed field ablation (PFA) ablation energy source potentially eases single shot PVI while increasing safety due to its non-thermal ablation. The so-called 5S strategy aimed to investigate safety and feasibility of single shot anatomic PFA ablation. Initial clinical experience in a large all-comer AF patient cohort including mechanisms of patients with atrial tachyarrhythmia recurrence will be reported.